You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: April 22, 2025

Details for Patent: 10,206,879


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 10,206,879 protect, and when does it expire?

Patent 10,206,879 protects CRESEMBA and is included in one NDA.

Protection for CRESEMBA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has eight patent family members in seven countries.

Summary for Patent: 10,206,879
Title:Active ingredient containing stabilised solid forms and method for the production thereof
Abstract: The invention relates to solid medicinal forms containing at least one active ingredient and at least one pharmaceutically compatible, water soluble drying agent which is selected from the group consisting of trimagnesium dicitrate and/or calcium chloride, the solid medicinal form having a drying loss of at most 6% and a relative equilibrium moisture content of 25% or less. The invention also relates to solid medicinal forms containing a moisture-sensitive active ingredient and trimagnesium dicitrate.
Inventor(s): Gruber; Peter (Merzhausen, DE), Spickermann; Dirk (Staufen, DE)
Assignee: Losan Pharma GmbH (Neuenburg, DE)
Application Number:15/705,599
Patent Claim Types:
see list of patent claims
Compound; Dosage form;
Patent landscape, scope, and claims:

Understanding the Scope and Claims of U.S. Patent 10,206,879: A Comprehensive Analysis

Introduction

U.S. Patent 10,206,879, like any other patent, is a complex document that outlines the invention, its scope, and the claims that define the intellectual property rights granted to the inventor. To analyze this patent, we need to delve into several key aspects, including the patent's subject matter, the claims, the prosecution history, and the broader patent landscape.

Subject Matter and Background

To begin with, it is crucial to understand the subject matter of the patent. U.S. Patent 10,206,879 would typically be categorized within a specific technological field, such as software, biotechnology, mechanical engineering, or another area. The background section of the patent usually provides context on the existing technology and the problems the invention aims to solve.

Patent Claims

Types of Claims

Patent claims are the heart of any patent, as they define the scope of the invention and the rights granted to the patent holder. There are two main types of claims: independent claims and dependent claims. Independent claims stand alone and define the invention without reference to other claims, while dependent claims refer back to and further limit the independent claims[3].

Claim Language and Scope

The language used in the claims is critical. Claims can be broad or narrow, and their scope is often a subject of debate. Broader claims may cover a wider range of variations of the invention but are more likely to face challenges during the examination process or in litigation. Narrower claims, while more specific, may offer stronger protection but cover a smaller scope of the invention[3].

Prosecution History

Continuation Applications

The prosecution history of a patent, including any continuation or continuation-in-part applications, can significantly impact the patent's scope and claims. Continuation applications allow patent applicants to keep their applications pending for extended periods, potentially leading to broader or more refined claims over time. This practice is common, with about 23% of all patents issued from 1976 through 2000 claiming priority to one or more previously filed applications[2].

Patent Term Adjustment (PTA) and Patent Term Extension (PTE)

The prosecution history may also involve adjustments to the patent term due to delays in the examination process (PTA) or extensions due to regulatory review (PTE). These adjustments can affect the overall term of the patent and are crucial in determining potential issues related to obviousness-type double patenting (ODP)[1].

Obviousness-Type Double Patenting (ODP)

ODP is a doctrine designed to prevent the extension of patent term beyond the statutory limit by filing multiple patents on the same or very similar inventions. If the claims of a later-expiring patent are obvious variants of those in an earlier-expiring patent, they may be deemed unpatentable under ODP. This is particularly relevant in cases involving continuation applications, where the expiration dates of related patents need to be carefully calculated to avoid ODP issues[1].

Patent Quality and Scope Metrics

The quality and scope of patent claims are often measured using metrics such as independent claim length and independent claim count. Research has shown that narrower claims at publication are associated with a higher probability of grant and a shorter examination process. The examination process itself tends to narrow the scope of patent claims, ensuring that the granted patents have clearer and more defined boundaries[3].

Litigation and Enforcement

Patents that issue from continuation applications are more likely to be litigated than those issued directly from original applications. This is because continuation patents often involve more complex and broader claims, which can lead to disputes over infringement and validity. The litigation history of related patents can provide insights into the potential risks and challenges associated with enforcing U.S. Patent 10,206,879[2].

Regulatory and Policy Context

The Bayh-Dole Act, for instance, plays a significant role in the patent landscape for inventions supported by federal funding. If U.S. Patent 10,206,879 is related to such inventions, the patent holder must comply with the Act's requirements, including providing the federal government with a government-use license[4].

Key Takeaways

  • Patent Claims: The scope and language of patent claims are critical in defining the invention and the rights granted.
  • Prosecution History: Continuation applications and adjustments to the patent term can significantly impact the patent's scope and validity.
  • ODP: Ensuring that the patent does not fall under ODP is crucial to maintaining its validity.
  • Patent Quality Metrics: Metrics such as independent claim length and count can help assess the quality and scope of the patent.
  • Litigation: Patents issued from continuation applications are more likely to be litigated, highlighting the need for careful claim drafting and prosecution.

FAQs

  1. What is the significance of independent claims in a patent? Independent claims define the invention without reference to other claims and are crucial in establishing the scope of the patent.

  2. How do continuation applications affect the patent term? Continuation applications can extend the prosecution time, potentially leading to broader or more refined claims, and may impact the patent term through PTA or PTE adjustments.

  3. What is obviousness-type double patenting (ODP)? ODP is a doctrine that prevents the extension of patent term beyond the statutory limit by filing multiple patents on the same or very similar inventions.

  4. How are patent quality and scope measured? Metrics such as independent claim length and independent claim count are used to measure patent quality and scope, with narrower claims often associated with a higher probability of grant and shorter examination processes.

  5. Why are patents issued from continuation applications more likely to be litigated? Patents issued from continuation applications often involve more complex and broader claims, which can lead to disputes over infringement and validity, making them more likely to be litigated.

Sources

  1. Duanemorris.com - Patent Term Adjustment and Patent Term Extension Analyzed Differently in Consideration of Obviousness-Type Double Patenting[1].
  2. Duke Law School - The Curious Practice of Continuing Patent Applications[2].
  3. Hoover Institution - Patent Claims and Patent Scope[3].
  4. CRS Reports - Pricing and March-In Rights Under the Bayh-Dole Act[4].

More… ↓

⤷  Try for Free


Drugs Protected by US Patent 10,206,879

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Astellas CRESEMBA isavuconazonium sulfate CAPSULE;ORAL 207500-002 Nov 22, 2022 RX Yes No ⤷  Try for Free ⤷  Try for Free Y ⤷  Try for Free
Astellas CRESEMBA isavuconazonium sulfate CAPSULE;ORAL 207500-001 Mar 6, 2015 RX Yes Yes ⤷  Try for Free ⤷  Try for Free Y ⤷  Try for Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 10,206,879

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
06020008Sep 25, 2006

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.